Milbemite (milbemycin)

Milbemite is a veterinary prescription otic solution containing milbemycin oxime, specifically formulated for the treatment of ear mite infestations in cats and kittens. Manufactured by Elanco (formerly Novartis Animal Health), Milbemite provides an effective single-dose treatment option for eliminating Otodectes cynotis, the ear mite species responsible for the overwhelming majority of parasitic ear conditions in domestic cats. The product contains 0.1% milbemycin oxime in a specialized vehicle designed for direct application to the ear canal. Ear mites are extremely common parasites in cats, with particularly high prevalence in kittens, shelter populations, and multi-cat households, making targeted treatments like Milbemite essential components of feline parasitology.

Milbemycin oxime, the active ingredient in Milbemite, belongs to the macrocyclic lactone class of antiparasitic compounds. This medication works by interfering with the neurotransmission in invertebrates, specifically targeting glutamate-gated chloride channels and gamma-aminobutyric acid (GABA) receptors found in invertebrate nerve and muscle cells. When milbemycin binds to these receptors, it causes an increased permeability to chloride ions, resulting in hyperpolarization of nerve and muscle cells. This leads to paralysis and death of the parasites. Importantly, mammalian chloride channels have different characteristics that make them much less susceptible to milbemycin's effects, providing an excellent safety margin for use in cats when applied as directed.

Milbemite is supplied as a ready-to-use otic solution in single-dose tubes, with each tube containing 0.5 mL of the milbemycin oxime solution. This packaging format ensures accurate dosing and eliminates the need for measuring, reducing the potential for dosing errors. Each tube provides the complete dose for treating one ear of a cat. The convenience of single-dose application makes treatment straightforward for cat owners and veterinary staff alike. Treatment typically involves application to both ears regardless of which ear shows clinical signs, as mites can migrate between ears and may be present in seemingly unaffected ears. A single treatment is often effective, though follow-up evaluation determines if repeat treatment is necessary.

The safety profile of Milbemite has been established through clinical studies supporting its FDA approval for use in cats four weeks of age and older. When used according to label directions, Milbemite is generally well-tolerated by feline patients. Veterinary diagnosis is essential before treatment to confirm ear mite infestation and ensure the ear canal is appropriate for medication application. Otoscopic examination and microscopic evaluation of ear debris are typically performed to identify mites before prescribing treatment. Following application, monitoring for resolution of clinical signs and follow-up veterinary evaluation ensure successful elimination of the parasites and allow identification of any cats requiring additional treatment or management.

The FDA-approved primary indication for Milbemite is the treatment of ear mite infestations caused by Otodectes cynotis in cats and kittens four weeks of age and older. Ear mites are microscopic arachnids that live primarily within the external ear canal, where they complete their entire life cycle over approximately three weeks. These parasites feed on tissue fluids and ear debris, causing significant irritation and inflammation of the ear canal lining. The presence of ear mites triggers intense itching, leading cats to scratch their ears excessively and shake their heads. The characteristic dark brown to black, crumbly discharge seen in mite-infested ears results from a combination of dried blood, mite waste products, ear wax, and inflammatory debris. Milbemite effectively eliminates these parasites, providing relief from the discomfort they cause.

Ear mite infestations are particularly common in certain feline populations, making effective treatment options like Milbemite critically important. Kittens frequently acquire ear mites from their mothers or littermates during the first weeks of life, as the parasites spread readily through close contact. Animal shelters and rescue organizations commonly see ear mite infestations due to the high-density housing of cats and the ease with which mites transfer between animals. Multi-cat households can experience outbreaks where mites spread throughout the population. Outdoor cats and those with exposure to other animals face increased risk of infestation. Stray and feral cat populations often harbor ear mites due to lack of veterinary care. For all these populations, prompt diagnosis and effective treatment are essential for controlling infestations.

While ear mites primarily inhabit the ear canal, they can occasionally be found on other areas of the body, particularly the head, neck, and tail base where cats may spread mites during grooming or scratching behaviors. This condition, sometimes called ectopic otodectic mange, represents mite presence outside their preferred ear canal habitat. Although Milbemite is specifically formulated for otic application and treats ear canal infestations, addressing ear mites also reduces the overall mite burden when mites have spread. In cases of significant ectopic infestation, your veterinarian may recommend additional systemic antiparasitic treatments or whole-body topical products to comprehensively address all mite populations.

Secondary complications frequently accompany ear mite infestations and may require additional treatment alongside Milbemite. The intense itching caused by mites leads to excessive scratching, which can cause wounds around the ears, head, and neck. Bacterial or yeast infections often develop as secondary problems due to the disrupted ear canal environment and trauma from scratching. These secondary infections may require separate treatment with appropriate antimicrobial ear medications in addition to mite treatment. Your veterinarian will evaluate whether your cat has concurrent infections requiring additional therapy and develop a comprehensive treatment plan addressing all aspects of the ear disease.

Veterinarians select Milbemite for ear mite treatment based on several factors that make it a favorable choice for many patients. The single-dose tube format provides convenient, accurate dosing without the need for measuring. The otic application delivers medication directly where mites reside, maximizing effectiveness against the parasites while limiting systemic drug exposure. The FDA approval specifically for cats ensures the product has undergone safety and efficacy evaluation in feline patients. For cats that may not tolerate oral medications or have conditions affecting systemic drug use, topical ear application provides an alternative delivery approach. Treatment compliance is often better with single-dose applications compared to multi-day treatment regimens.

The dosing protocol for Milbemite is straightforward, designed around the single-dose tube presentation specifically created for feline patients. Each single-dose tube contains 0.5 mL of milbemycin oxime otic solution, representing the complete dose for one ear. For cats with ear mite infestations, the entire contents of one tube should be administered into each ear canal. Both ears should be treated even when only one ear appears clinically affected, as ear mites can be present in ears without obvious signs and readily migrate between ears. The product is approved for cats and kittens four weeks of age and older, and the same single-tube-per-ear dose applies regardless of the cat's body weight due to the local nature of otic administration.

The standard treatment regimen for Milbemite consists of a single treatment application to each ear, with veterinary follow-up recommended approximately two to four weeks after treatment. During this follow-up, your veterinarian will examine the ears to determine whether the initial treatment successfully eliminated the mites or whether a second treatment is necessary. In many cases, a single application effectively eradicates the ear mite population. However, some infestations may require repeat treatment to address mites that were in early developmental stages less susceptible to treatment at the time of initial application, or in cases of reinfestation from untreated contact animals. Do not repeat treatment without veterinary direction.

Treatment duration considerations for ear mites differ from many other feline medications in that Milbemite is designed as a single-application treatment rather than a daily treatment course over multiple days or weeks. However, the complete treatment timeline encompasses the waiting period before reassessment, typically two to four weeks. During this interval, the medication continues working, and any remaining mites and their eggs progress through their life cycle. Clinical signs such as itching, head shaking, and dark discharge typically begin improving within one to two weeks as the inflammation subsides and the ear environment normalizes. If symptoms persist or worsen beyond two weeks, contact your veterinarian for reevaluation.

Proper administration technique maximizes the effectiveness of Milbemite treatment. Before application, gently wipe visible debris from the outer ear using a cotton ball or soft gauze, but do not insert anything deep into the ear canal unless specifically directed by your veterinarian. Your veterinarian may clean the ears professionally before treatment or may recommend cleaning at home prior to medication application. Twist off or cut the tip of the single-dose tube to open it. Hold your cat securely, lifting the ear flap gently upward to straighten the ear canal. Insert the tube tip just inside the ear canal opening without forcing it deep into the canal. Squeeze the tube completely to expel all contents into the ear. After application, gently massage the base of the ear for fifteen to twenty seconds to help distribute the medication throughout the canal. Repeat with a new tube for the other ear.

Because Milbemite is formulated as a single-dose treatment, the concept of missed doses does not apply in the traditional medication sense. However, if you are unable to complete treatment of both ears in one session, contact your veterinarian for guidance on how to proceed. If a follow-up treatment is recommended and you cannot keep the appointment, reschedule promptly to ensure appropriate treatment completion. Do not stockpile Milbemite tubes for future use without veterinary guidance, as proper diagnosis should precede each treatment episode to ensure ear mites are actually present and that no other conditions are causing similar symptoms.

Post-treatment care and follow-up are important components of successful ear mite management. Attend the recommended recheck appointment to confirm treatment success. Complete any additional treatments prescribed for secondary bacterial or yeast infections. In multi-cat households, all cats should be examined and potentially treated simultaneously to prevent reinfestation from untreated animals, even those without obvious symptoms. Environmental cleaning, while less critical than with some other parasites since ear mites survive only briefly off hosts, can help reduce any environmental contamination. Contact your veterinarian if symptoms do not improve within one to two weeks, if symptoms return after initial improvement, or if any unusual reactions occur following treatment.

Milbemite is generally well-tolerated by most cats when used according to label directions for the treatment of ear mite infestations. The otic route of administration delivers the medication directly to the ear canal, which limits systemic absorption and reduces the likelihood of body-wide adverse effects compared to oral or injectable medications. Clinical trials conducted for FDA approval demonstrated a favorable safety profile in cats four weeks of age and older. As with any medication, individual cats may experience adverse reactions, and awareness of potential side effects allows cat owners to monitor their pets appropriately and seek veterinary attention when needed.

The most commonly observed side effects of Milbemite involve localized reactions within or around the treated ear. Some cats may exhibit temporary head shaking, ear scratching, or pawing at the ears shortly after medication administration. These behaviors often represent responses to the sensation of liquid in the ear canal rather than true adverse reactions and typically resolve within minutes to hours after application. Mild local irritation, manifesting as temporary redness or discomfort in the ear, may occur in some cats. These mild local effects usually resolve spontaneously without intervention and do not necessitate discontinuation of treatment.

Moderate side effects, while less common than mild local reactions, may occur in some cats. Signs of more significant local irritation include persistent head shaking or ear scratching that continues beyond the first day after treatment, noticeable increase in redness or swelling within the ear canal, or apparent pain when the ear is touched. Systemic absorption of milbemycin, though limited with otic application, could theoretically produce effects similar to those seen with oral milbemycin products. These might include gastrointestinal signs such as vomiting, diarrhea, or decreased appetite, or neurological signs such as lethargy, ataxia, or tremors. If any of these signs occur following Milbemite application, contact your veterinarian for guidance.

Serious adverse reactions to Milbemite are rare but warrant immediate veterinary attention if they occur. Signs of severe allergic reaction include facial swelling, hives, difficulty breathing, or collapse, and these require emergency veterinary care. Significant neurological depression, severe ataxia (uncoordinated movement), seizures, blindness, or coma would indicate severe toxicity and require immediate veterinary intervention. These severe reactions are exceptionally rare with the otic product when used as directed. Ototoxicity (damage to ear structures) has not been specifically documented with Milbemite but is a theoretical concern with any ear medication if the eardrum is perforated. Signs potentially indicating ototoxicity include head tilt, circling, loss of balance, abnormal eye movements, or hearing changes.

Unlike certain dog breeds with the MDR1 gene mutation that causes severe sensitivity to macrocyclic lactones, cats do not have this specific genetic susceptibility. However, individual sensitivity can occur in any animal, and certain populations may be at higher risk for adverse effects. Very young kittens under four weeks of age have incompletely developed blood-brain barriers and are therefore more susceptible to central nervous system effects from absorbed medication, which is why the product is not approved for this age group. Debilitated, sick, or underweight cats may have increased sensitivity to medications. Cats with pre-existing neurological conditions should be treated with awareness that any additional neurological effects would be concerning. Report any adverse reactions to your veterinarian and consider reporting to the medication manufacturer or FDA.

Milbemite should not be used in cats with known hypersensitivity or allergy to milbemycin oxime or other macrocyclic lactone compounds. Cats that have previously experienced adverse reactions to milbemycin, ivermectin, selamectin, moxidectin, or related antiparasitic agents should not receive Milbemite without careful veterinary evaluation of risks and benefits. Cross-reactivity among compounds in this drug class can occur, meaning that a cat sensitive to one macrocyclic lactone may react to others. Previous adverse reactions to any product in this class should be disclosed to your veterinarian before Milbemite is prescribed. Allergic reactions can range from mild local irritation to severe systemic responses.

Milbemite is not approved for use in kittens under four weeks of age, representing an important age-based contraindication. Very young kittens have immature blood-brain barriers that may allow greater penetration of milbemycin into the central nervous system, potentially increasing the risk of neurological adverse effects. Additionally, kittens under four weeks have immature liver and kidney function affecting drug metabolism and elimination. While ear mite infestations are common in young kittens (often acquired from their mothers), treatment with Milbemite should be delayed until kittens reach four weeks of age. Alternative management approaches for very young kittens with severe infestations should be discussed with your veterinarian, who can weigh the risks and benefits in specific cases.

Perforated or ruptured tympanic membrane (eardrum) represents a significant contraindication for Milbemite use. The intact eardrum serves as a barrier protecting the middle and inner ear from substances applied to the external ear canal. When perforation exists, ear medications can penetrate into deeper ear structures, potentially causing inflammation, infection, or damage to the vestibular and auditory systems. Ear mites and severe ear infections can cause eardrum damage, and this damage may not be apparent without otoscopic examination by a veterinarian. Signs that might suggest eardrum perforation include severe or chronic ear infection, head tilt, balance problems, or unusual discharge. Veterinary examination to assess eardrum integrity should precede any ear treatment.

Certain medical conditions and physiological states warrant caution or contraindicate Milbemite use. The safety of Milbemite in pregnant cats has not been specifically established, and milbemycin oxime crosses the placenta in other species. While systemic absorption from otic application is limited, pregnant cats should only receive Milbemite when the veterinarian determines benefits outweigh potential risks. Similarly, nursing queens require careful consideration, as milbemycin can be excreted in milk, potentially exposing nursing kittens. Severely debilitated, ill, or underweight cats may have altered drug sensitivity and require careful evaluation. Cats with known neurological conditions should be treated with caution, as any medication-related neurological effects would be of particular concern in these patients.

Providing your veterinarian with complete information about all medications, supplements, and treatments your cat is receiving is important before Milbemite administration. While significant drug interactions with topical otic Milbemite are less common than with systemically administered medications due to limited absorption from ear application, potential interactions should still be considered. Complete disclosure of all current treatments, including flea and parasite preventatives, prescription medications, over-the-counter products, and dietary supplements, allows your veterinarian to assess any interaction concerns and develop the safest treatment approach for your cat.

The most relevant potential interactions involve other medications within the macrocyclic lactone class or those affecting similar neurological targets. Products containing ivermectin, selamectin, moxidectin, or milbemycin (the same active ingredient as Milbemite, used in oral heartworm preventives) share mechanisms of action. Using multiple macrocyclic lactone products concurrently could theoretically increase the risk of adverse effects through additive activity, though this concern is reduced with otic administration compared to systemic products. If your cat is receiving a monthly parasite preventive containing a macrocyclic lactone, inform your veterinarian before Milbemite treatment. Drugs affecting GABA receptors or chloride channels, including certain sedatives, anticonvulsants, and anesthetics, could potentially have additive effects with absorbed milbemycin.

Milbemycin is metabolized by the liver, primarily through cytochrome P450 enzyme systems. Drugs that inhibit or induce these enzymes could theoretically affect milbemycin blood levels if significant absorption occurs from the otic product. Ketoconazole and other azole antifungals inhibit cytochrome P450 enzymes and have been associated with increased blood levels of some macrocyclic lactones. Drugs affecting P-glycoprotein function, which helps prevent certain drugs from crossing the blood-brain barrier, could theoretically increase central nervous system exposure to milbemycin. While these interactions are more relevant for systemic milbemycin products, awareness is appropriate for cats on multiple medications, especially with extended or repeated Milbemite use.

Concurrent use of other ear products should be discussed with your veterinarian when Milbemite treatment is planned. Using multiple otic medications simultaneously can affect drug distribution, absorption, and efficacy. Ear cleaning solutions are often used before ear mite treatment to remove debris, but timing should be coordinated so the ear is reasonably dry before Milbemite application. If secondary bacterial or yeast infections require treatment alongside mite therapy, your veterinarian will provide specific instructions about timing and sequence of different ear products. Some combination otic products contain antiparasitic agents along with antimicrobial components and might be considered as alternatives to using multiple separate products. Always follow your veterinarian's specific guidance regarding the use of multiple ear treatments.

General precautions for Milbemite use emphasize the importance of accurate diagnosis before treatment and appropriate monitoring after application. Ear mite symptoms, including scratching, head shaking, and dark discharge, can resemble other ear conditions such as bacterial infections, yeast infections, and allergies. Treating based on symptoms alone without proper diagnosis could delay appropriate care for conditions that do not respond to antiparasitic therapy. Milbemite should only be administered following veterinary examination confirming ear mite infestation through otoscopic examination and/or microscopic identification of mites in ear debris. The medication is intended for otic use only and should not be administered orally, applied to skin, or used in species other than cats without specific veterinary direction.

Breed-specific sensitivities to milbemycin have not been documented in cats in the way that certain dog breeds demonstrate ivermectin sensitivity. Cats lack the MDR1 gene mutation that causes severe macrocyclic lactone toxicity in Collies and related dog breeds. However, individual variation in drug response exists across all cat breeds and mixed-breed cats. Some Oriental breed cats have been anecdotally suggested to have heightened sensitivity to certain medications, though this has not been specifically demonstrated for milbemycin products. Regardless of breed, all cats should be observed after Milbemite application for any signs of adverse reactions. First-time use of macrocyclic lactone products in any cat warrants careful monitoring.

Handling and environmental precautions protect both the patient and household members during treatment. Wash hands thoroughly with soap and water after handling the medication and applying it to your cat's ears. Avoid contact with your own eyes, skin, or mucous membranes during application. If human exposure occurs, wash the affected area thoroughly; if eye exposure occurs, rinse with water and consult a healthcare provider if irritation persists. Keep Milbemite out of reach of children and other pets when not in use. In multi-cat households, prevent cats from grooming each other's treated ears immediately after application, as this could result in oral ingestion of medication by the grooming cat.

Monitoring your cat following Milbemite treatment allows assessment of both treatment efficacy and safety. Watch for resolution of ear mite symptoms, including decreased scratching, reduced head shaking, and improvement in ear discharge, typically expected within one to two weeks. Also observe for any adverse reactions, particularly in the hours immediately following application. Neurological signs (unsteadiness, lethargy, dilated pupils, tremors), signs of allergic reaction (facial swelling, breathing difficulty), or significant worsening of local ear symptoms should prompt veterinary contact. Keep the scheduled follow-up appointment to confirm treatment success and determine whether additional treatment is needed.

Special feline populations require additional consideration when using Milbemite. Kittens at the minimum approved age of four weeks represent the youngest population in which the product can be used and should be monitored especially carefully. Geriatric cats may have age-related changes affecting drug handling and should be observed for any unusual responses. Cats with liver or kidney disease may have altered drug metabolism or elimination, though this is less concerning with topical otic application. Immunocompromised cats may have concurrent infections requiring additional management. Pregnant and nursing cats should only be treated when necessary under veterinary supervision. Cats with any concurrent illness should be evaluated holistically to ensure Milbemite treatment is appropriate alongside other health management.

Proper storage of Milbemite maintains product stability and ensures effectiveness when the medication is used. Store Milbemite at controlled room temperature between 68°F and 77°F (20°C to 25°C), protecting from temperature extremes. Avoid storing the product in hot environments such as vehicles, near heating vents, or in direct sunlight, as excessive heat can degrade the active ingredient. Do not freeze the product, as freezing may affect the formulation's integrity. Keep the medication in its original packaging until ready to use, as the packaging protects the single-dose tubes from light and environmental exposure. Check the expiration date before use and do not use expired product.

The single-dose tube format of Milbemite has specific handling requirements. Each tube is designed for one-time use in one ear and should be disposed of after the contents are expelled, even if a small amount appears to remain in the tube. Do not attempt to save partially used tubes for later use, as the opened product may become contaminated or lose effectiveness. When opening the tube, cut or twist off the tip carefully to create a clean opening for application. Avoid touching the tube tip to contaminated surfaces before insertion into the ear canal to prevent introduction of bacteria or debris into the solution. When treating multiple cats, use separate tubes for each animal and each ear to prevent cross-contamination between animals.

Safe handling and disposal practices protect your household and the environment. Keep Milbemite in a secure location out of reach of children and other pets when not in use. Accidental ingestion by children or animals could result in adverse effects. Supervise cats after treatment to prevent mutual grooming that could result in oral exposure to a housemate cat. Dispose of used tubes and packaging according to local guidelines for pharmaceutical waste. Do not flush unused medication or used tubes down toilets or drains. Many veterinary clinics participate in drug take-back programs for proper pharmaceutical disposal. If take-back programs are unavailable in your area, consult your veterinarian or local waste management authority for guidance on appropriate disposal methods.

Cats of all breeds generally tolerate Milbemite well, and breed-specific adverse reactions to milbemycin have not been documented in felines. Unlike certain dog breeds that carry the MDR1 gene mutation causing severe sensitivity to macrocyclic lactone drugs, cats do not appear to have an equivalent genetic predisposition. This provides favorable safety expectations for milbemycin use across the diverse range of cat breeds. Individual variation in drug response exists within any breed, however, and unexpected reactions can occur in any individual cat. Veterinary treatment approaches for ear mites remain consistent across breeds while maintaining vigilance for individual patient responses.

Certain breed characteristics may influence ear health patterns and ear mite susceptibility, though not necessarily Milbemite sensitivity. Scottish Fold cats have distinctive folded ear pinnae resulting from cartilage abnormality, which does not affect the ear canal where mites reside and treatment is applied. Persian and Himalayan cats may have more ear hair and potentially narrower ear canals relative to some other breeds, factors that can affect debris accumulation and possibly mite environment. Devon Rex and Cornish Rex cats have characteristically large ear openings relative to their head size. Sphynx cats lack ear hair and may accumulate more visible debris. While these breed characteristics affect ear care practices generally, they do not indicate altered sensitivity to Milbemite specifically.

Body size varies among cat breeds and may slightly affect practical aspects of ear treatment, though dosing with Milbemite single-dose tubes is standardized. Large breed cats such as Maine Coons, Norwegian Forest Cats, and Ragdolls have proportionally larger ear canals, while smaller cats have smaller canals. The 0.5 mL volume per tube is designed to be appropriate for the typical range of cat ear canal sizes. Very small cats or young kittens at the minimum approved age may have smaller ear canals relative to the solution volume. Conversely, very large cats have larger canals that readily accommodate the standard dose. Your veterinarian can advise if any modifications to standard treatment approach are appropriate for your individual cat's size or anatomy.

Age intersects with breed in determining appropriate ear mite treatment considerations. Purebred kittens acquired from breeders or catteries may have high ear mite exposure due to the multi-cat environment in breeding facilities. Shelter cats of any breed background commonly present with ear mites. Senior cats of all breeds may have age-related changes in drug handling and overall health status that affect treatment decisions. Regardless of breed or age, all cats receiving Milbemite should be monitored after treatment for both efficacy and adverse reactions. Follow-up veterinary examination ensures treatment success and identifies any cats requiring additional intervention or management.

Several other medications are available for treating ear mite infestations in cats, providing alternatives when Milbemite is not suitable or when different treatment characteristics are preferred. Acarexx (ivermectin otic solution) is another FDA-approved single-dose ear mite treatment for cats, using a different macrocyclic lactone compound. Systemic antiparasitic products that treat ear mites along with other parasites include Revolution and Revolution Plus (selamectin-based topical products), Advantage Multi (imidacloprid and moxidectin), and Bravecto Plus (fluralaner and moxidectin). These monthly topical or extended-duration products provide broad-spectrum parasite protection and may be preferred when concurrent flea, heartworm, or intestinal parasite treatment is needed, or when otic application is particularly challenging.

Combination otic products that address both ear mites and secondary infections represent another treatment category. Tresaderm contains thiabendazole with antiparasitic activity against ear mites, combined with neomycin for bacterial infections and dexamethasone for inflammation. This multi-action approach addresses the common scenario where ear mite infestation is complicated by secondary bacterial or yeast infection. While not single-agent mite treatments like Milbemite, these combination products offer comprehensive treatment when multiple ear problems coexist. Your veterinarian will determine whether a focused antiparasitic treatment like Milbemite or a combination product is more appropriate based on your cat's specific ear condition and any secondary infections present.

Supportive treatments and environmental management complement ear mite medication regardless of which specific product is used. Gentle ear cleaning before treatment can help remove debris, though specific cleaning protocols should follow veterinary recommendations. In multi-cat households, examining and potentially treating all cats simultaneously is important to prevent reinfestation, as ear mites readily spread between animals in close contact. Environmental cleaning has limited impact since ear mites survive only briefly away from their host, but washing bedding and cleaning areas where infected cats rest can reduce any environmental mite presence. Never substitute over-the-counter products or home remedies for veterinary-prescribed ear mite treatment, as inappropriate treatment delays resolution and may cause harm. Your veterinarian can recommend the most appropriate treatment approach based on your cat's individual situation, the presence of other parasites, and any concurrent ear conditions.